ArticleJournal of hepatocellular carcinoma2026
Gustave Roussy Immune Score Predicts Outcomes in Hepatocellular Carcinoma Treated with TACE and Immunotherapy.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prognostic value of the Gustave Roussy Immune (GRIm) score and the hepatocellular carcinoma-specific GRIm (HCC-GRIm) score in unresectable hepatocellular carcinoma (uHCC) treated with transarterial chemoembolization (TACE) plus immune checkpoint inhibitors (ICIs) and anti-VEGF antibodies/tyrosine kinase inhibitors (TKIs), and to examine their association with hepatitis B virus (HBV) activation and immune markers. Methods: This retrospective study enrolled uHCC patients receiving TACE plus ICIs and anti-VEGF antibodies/TKIs. Baseline blood tests were used to calculate GRIm and HCC-GRIm scores and determine HBV activation (HBV DNA > 60 IU/mL). Patients were stratified by GRIm, HCC-GRIm, and HBV activation. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and peripheral immune markers were compared across groups. Cox regression identified independent prognostic factors, and the prognostic value of key predictors was compared with Barcelona Clinic Liver Cancer (BCLC) and China Liver Cancer (CNLC) staging systems. Results: Sixty-seven patients were included. ORR and DCR were 53.7% and 86.6%; median OS was 30.4 months. High GRIm and HCC-GRIm scores were associated with shorter OS than low scores (GRIm: 15.4 vs 34.0 months, Conclusion: GRIm and HCC-GRIm are effective prognostic indicators in uHCC patients treated with TACE plus ICIs and anti-VEGF antibodies/TKIs, reflecting systemic immune and inflammatory status. Both scores retain prognostic value regardless of pre-treatment HBV activation but do not predict tumor response. In this single-center cohort, GRIm provided prognostic discrimination comparable to HCC-GRIm, and CD3⁺CD8⁺ T-cell stratification also showed prognostic value, offering an additional approach for risk assessment. Future larger, multicenter studies are needed to validate these findings and to define the optimal roles of GRIm, HCC-GRIm, and CD3⁺CD8⁺-based stratification in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.